Tolga Gidener1,2, Meng Yin1, Ross A Dierkhising3, Alina M Allen2, Richard L Ehman1, Sudhakar K Venkatesh1. 1. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. 2. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 3. Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND AND AIMS: Although magnetic resonance elastography (MRE) has been well-established for detecting and staging liver fibrosis, its prognostic role in determining outcomes of chronic liver disease (CLD) is mostly unknown. APPROACH AND RESULTS: This retrospective study consisted of 1269 subjects who underwent MRE between 2007 and 2009 and followed up until death or last known clinical encounter or end of study period. Charts were reviewed for cirrhosis development, decompensation, and transplant or death. The cohort was split into baseline noncirrhosis (group 1), compensated cirrhosis (group 2), and decompensated cirrhosis (group 3). Cox-regression analysis with age, sex, splenomegaly, CLD etiology, Child-Pugh Score (CPS), Fibrosis-4 Index (FIB-4) score, and Model for End-Stage Liver Disease (MELD)-adjusted HR for every 1-kPa increase in liver stiffness measurement (LSM) were used to assess the predictive performance of MRE on outcomes. Group 1 (n = 821) had baseline median LSM of 2.8 kPa, and cirrhosis developed in 72 (8.8%) subjects with an overall rate of about 1% cirrhosis/year. Baseline LSM predicted the future cirrhosis with multivariable adjusted HR of 2.38 (p < 0.0001) (concordance, 0.84). In group 2 (n = 277) with baseline median LSM of 5.7 kPa, 83 (30%) subjects developed decompensation. Baseline LSM predicted the future decompensation in cirrhosis with FIB-4 and MELD-adjusted HR of 1.22 (p < 0.0001) (concordance, 0.75). In group 3 (n = 171) with median baseline LSM of 6.8 kPa (5.2, 8.4), 113 (66%) subjects had either death or transplant. Baseline LSM predicted the future transplant or death with HR of 1.11 (p = 0.013) (concordance 0.53) but not in CPS and MELD-adjusted models (p = 0.08). CONCLUSION: MRE-based LSM is independently predictive of development of future cirrhosis and decompensation, and has predictive value in future transplant/death in patients with CLD.
BACKGROUND AND AIMS: Although magnetic resonance elastography (MRE) has been well-established for detecting and staging liver fibrosis, its prognostic role in determining outcomes of chronic liver disease (CLD) is mostly unknown. APPROACH AND RESULTS: This retrospective study consisted of 1269 subjects who underwent MRE between 2007 and 2009 and followed up until death or last known clinical encounter or end of study period. Charts were reviewed for cirrhosis development, decompensation, and transplant or death. The cohort was split into baseline noncirrhosis (group 1), compensated cirrhosis (group 2), and decompensated cirrhosis (group 3). Cox-regression analysis with age, sex, splenomegaly, CLD etiology, Child-Pugh Score (CPS), Fibrosis-4 Index (FIB-4) score, and Model for End-Stage Liver Disease (MELD)-adjusted HR for every 1-kPa increase in liver stiffness measurement (LSM) were used to assess the predictive performance of MRE on outcomes. Group 1 (n = 821) had baseline median LSM of 2.8 kPa, and cirrhosis developed in 72 (8.8%) subjects with an overall rate of about 1% cirrhosis/year. Baseline LSM predicted the future cirrhosis with multivariable adjusted HR of 2.38 (p < 0.0001) (concordance, 0.84). In group 2 (n = 277) with baseline median LSM of 5.7 kPa, 83 (30%) subjects developed decompensation. Baseline LSM predicted the future decompensation in cirrhosis with FIB-4 and MELD-adjusted HR of 1.22 (p < 0.0001) (concordance, 0.75). In group 3 (n = 171) with median baseline LSM of 6.8 kPa (5.2, 8.4), 113 (66%) subjects had either death or transplant. Baseline LSM predicted the future transplant or death with HR of 1.11 (p = 0.013) (concordance 0.53) but not in CPS and MELD-adjusted models (p = 0.08). CONCLUSION: MRE-based LSM is independently predictive of development of future cirrhosis and decompensation, and has predictive value in future transplant/death in patients with CLD.
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Mi Na Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn Journal: J Clin Gastroenterol Date: 2014-03 Impact factor: 3.062
Authors: Karim T Osman; Daniel B Maselli; Ilkay S Idilman; Daniel J Rowan; Jason K Viehman; William S Harmsen; Denise M Harnois; Elizabeth J Carey; Andrea A Gossard; Nicholas F LaRusso; Keith D Lindor; Sudhakar K Venkatesh; John E Eaton Journal: J Clin Gastroenterol Date: 2021 May-Jun 01 Impact factor: 3.062
Authors: Tolga Gidener; Omar T Ahmed; Joseph J Larson; Kristin C Mara; Terry M Therneau; Sudhakar K Venkatesh; Richard L Ehman; Meng Yin; Alina M Allen Journal: Clin Gastroenterol Hepatol Date: 2020-09-30 Impact factor: 13.576
Authors: Jonel Trebicka; Wenyi Gu; Victor de Ledinghen; Christophe Aubé; Aleksander Krag; Michael Praktiknjo; Laurent Castera; Jerome Dumortier; David Josef Maria Bauer; Mireen Friedrich-Rust; Stanislas Pol; Ivica Grgurevic; Rongqin Zheng; Sven Francque; Halima Gottfriedovà; Sanda Mustapic; Ioan Sporea; Annalisa Berzigotti; Frank Erhard Uschner; Benedikt Simbrunner; Maxime Ronot; Christophe Cassinotto; Maria Kjaergaard; Filipe Andrade; Martin Schulz; Georg Semmler; Ida Tjesic Drinkovic; Johannes Chang; Maximilian Joseph Brol; Pierre Emmanuel Rautou; Thomas Vanwolleghem; Christian P Strassburg; Jerome Boursier; Philip Georg Ferstl; Ditlev Nytoft Rasmussen; Thomas Reiberger; Valerie Vilgrain; Aymeric Guibal; Olivier Guillaud; Stefan Zeuzem; Camille Vassord; Xue Lu; Luisa Vonghia; Renata Senkerikova; Alina Popescu; Cristina Margini; Wenping Wang; Maja Thiele; Chrisitan Jansen Journal: Gut Date: 2021-01-21 Impact factor: 23.059